Vir Biotechnology, Inc. (VIR)
Nasdaq · Healthcare · Biotechnology
$11.78+5.46%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.0B
- 52-week range
- $4.82 – $11.94
- 52-week change
- +97.35%
- EPS (trailing)
- −$1.76
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $68.6M (−7.61%)
- Net income
- −$438M
- Operating margin
- −699.2%
- Diluted EPS
- −$3.16
- Free cash flow
- −$397M
From the company’s annual report on SEC EDGAR.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc.
Headquarters: San Francisco, United States · 367 employees · vir.bio